Scalper1 News
Receptos (RCPT) stock leapt 37% in massive volume to close at 39.94 in the stock market today, following Monday’s late announcement that its oral multiple-sclerosis drug RPC-1063 had reduced brain lesions in a phase-two clinical trial. RPC-1063 is chemically similar to Novartis’ (NVS) Gilenya, but Leerink analyst Marko Kozul wrote in a note Monday that the trial results “suggest it is meaningfully differentiated from Gilenya and other competing Scalper1 News
Scalper1 News